Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021)

Historic Preferred Stock Liabilities for TScan Therapeutics (TCRX) over the last 2 years, with Q2 2021 value amounting to $159.4 million.

  • TScan Therapeutics' Preferred Stock Liabilities changed N/A to $159.4 million in Q2 2021 from the same period last year, while for Jun 2021 it was $159.4 million, marking a year-over-year change of. This contributed to the annual value of $59.7 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q2 2021, TScan Therapeutics' Preferred Stock Liabilities is $159.4 million.
  • In the past 5 years, TScan Therapeutics' Preferred Stock Liabilities registered a high of $159.4 million during Q1 2021, and its lowest value of $59.7 million during Q4 2020.